PTGX Stock — Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc. (PTGX)

Updated October 16, 2026.

PTGX is a Stock. Total return is 1000.4% over the past 10.2 years, 689.6 points ahead of SPY at 310.8%.

Protagonist Therapeutics is a clinical-stage biopharmaceutical company developing targeted oral peptides and injectable therapies for immune-mediated and rare blood disorders, with its most advanced candidate, Icotyde, in development for plaque psoriasis and other programs addressing obesity, atopic dermatitis, asthma, and polycythemia vera. The company does not currently have an established distribution schedule. This security appeals to investors with a high risk tolerance for early-stage drug development and no need for current income.

PTGX performance versus SPY

Price and return data through 2026-10-16.

Total return is 1000.4% over the past 10.2 years, 689.6 points ahead of SPY at 310.8%. Over the past year its total return — price change plus distributions reinvested — is 70.0%. Its deepest 1-year drawdown was 18.8%.

PTGX key facts

Asset type

Stock

Asset class

Equity

Inception date

08/11/2016

Distribution frequency

None

Last close

$128.75 (as of 2026-10-16)

Market cap

$8,331,191,694

Average volume

886732.0

Beta

1.524

Payout ratio

0.0%

P/E ratio

127.48

Forward P/E

36.9004

EPS

$1.01

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

PTGX risks and drawbacks

The deepest 1-year drawdown on record here is 18.8%.

Who may consider PTGX — and who may not

It is a weaker fit for investors who need monthly cash flow (PTGX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on PTGX

• ETFs holding PTGX
• All tickers starting with P

Tagged: Healthcare.

Frequently asked questions